Hasselblom Sverker, Ridell Börje, Nilsson-Ehle Herman, Andersson Per-Ola
Department of Medicine, Section of Haematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden.
Leuk Lymphoma. 2007 Apr;48(4):736-45. doi: 10.1080/10428190601187703.
Most studies concerning therapy and prognosis in diffuse large B-cell lymphoma (DLBCL) are based on highly selected patient material. To evaluate treatment, clinical prognostic factors, and outcome in a population-based cohort, we performed a retrospective study comprising 535 de novo DLBCL patients in western Sweden, diagnosed between 1995 and 2000. The median age was 73 years. Treatment with a curative intent was administered to 376 (70%) patients. The International Prognostic Index (IPI) strongly predicted overall (OS) and progression-free (PFS) survival, but high age (>68 vs < or = 68 years) had no significant influence on response rate (p = 0.86) or PFS (p = 0.14). Male sex had a negative impact on both OS (p < 0.001) and PFS (p < 0.001), independent of IPI. In conclusion, a considerable proportion of the patients did not receive curative treatment, but among those treated, the response and PFS were not influenced by age. As men had lower PFS and OS than women, it seems important that gender perspective be taken into account in future studies.
大多数关于弥漫性大B细胞淋巴瘤(DLBCL)治疗和预后的研究都基于高度选择的患者群体。为了评估基于人群队列中的治疗、临床预后因素及结局,我们进行了一项回顾性研究,纳入了1995年至2000年间在瑞典西部诊断的535例初发性DLBCL患者。中位年龄为73岁。376例(70%)患者接受了根治性治疗。国际预后指数(IPI)强烈预测总生存期(OS)和无进展生存期(PFS),但高龄(>68岁与≤68岁)对缓解率(p = 0.86)或PFS(p = 0.14)无显著影响。男性性别对OS(p < 0.001)和PFS(p < 0.001)均有负面影响,且独立于IPI。总之,相当一部分患者未接受根治性治疗,但在接受治疗的患者中,缓解情况和PFS不受年龄影响。由于男性的PFS和OS低于女性,因此在未来研究中考虑性别因素似乎很重要。